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Abstract: Purpose: Glaucoma is a progressive optic neuropathy that may lead to blindness. Reducing intraocular pressure 
(IOP) seems to be the only treatment that slows progression in glaucoma. IOP can be decreased by pharmaceutical 
treatment, laser treatment or surgery. 
The aim of the present study was to assess the long-term efficacy of selective laser trabeculoplasty (SLT) treatment. 
Methods: Retrospective chart review of eyes that underwent SLT between 1 January 2005 and 31 December 2005. The 
primary outcome measure was time to failure after SLT treatment. Failure after SLT was defined as any one or more of 
the following: change in the medical treatment, performance of a further SLT treatment, the patient being sent for surgery. 
All patients were treated over 90° with SLT. 
Results: 120 eyes of 120 patients were identified. The average time to failure after SLT was 18 months. The success rate 
after 12 months was 62%, after 24 months 34%, after 36 months 28% and after 48 months 24%. 
Conclusions: The long-term effects of SLT when eyes were treated over 90° seem to be low. The authors recommend 
treating patients over 180°, as has traditionally been done. We suggest that this will improve the long-term results. 
Keywords: Glaucoma, laser, intraocular pressure. 
INTRODUCTION 
  Glaucoma is a progressive neuropathy localized in the 
optic nerve that may lead to blindness. Reducing intraocular 
pressure (IOP) seems to be the only treatment that slows 
progression in glaucoma. There are several methods to 
reduce IOP: pharmaceutical treatment, laser treatment and 
surgery. In the Glaucoma Laser Trial Follow-up study, after 
7 years of follow-up patients who had undergone argon laser 
trabeculoplasty (ALT) had lower IOP than patients taking 
drugs [1, 2]. However, in selective laser trabeculoplasty 
(SLT) there is still not sufficient evidence to determine the 
effectiveness of laser trabeculoplasty compared to 
medication. Laser trabeculoplasty appears to be less costly 
than current pharmaceutical treatment [3]. 
  Argon laser trabeculoplasty (ALT) was introduced about 
25 years ago and involves the use of a blue/green argon laser 
(major wavelength peaks at 488 nm and 514 nm) to treat the 
outer part of the trabecular meshwork and thereby improve 
aqueous flow and thus reduce IOP. Selective Laser 
Trabeculoplasty (SLT) is a rather new treatment alternative. 
It involves using a frequency-doubled q-switched Nd:YAG 
laser (532 nm) that delivers a low-energy, large-spot, very 
brief pulse to selectively target cells of the trabecular 
meshwork. This “gentler” laser application is thought to 
stimulate the pigmented trabecular meshwork cells and thus 
facilitate improved aqueous outflow. SLT treatment may 
hold clinical advantages over ALT treatment. 
  Long-term follow up after SLT treatment has been 
reported by Gracner T et al. [4] and shows a success rate of 
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58% after 48 months. Weinand FS & Althen F [5] showed a 
4-year success rate of 44% after SLT treatment. Juzych et al. 
[6] in a retrospective study comparing ALT with SLT 
reported a 4-year success rate of 32% after SLT treatment. In 
all the above mentioned studies 180 degrees of the trabecular 
meshwork was treated. 
  The aim of the present study was to determine whether 
the long-term (4 years) efficacy of SLT treatment was 
maintained when only 90 degrees of the trabecular 
meshwork was treated. 
MATERIALS AND METHODS 
  This was a retrospective chart review of patients treated 
from 1
st January 2005 till 31
st December 2005. Inclusion 
criteria were open-angle glaucoma (primary open angle, 
pseudoexfoliation or pigmentary glaucoma) and ocular 
hypertensive (OHT) patients, older than 18 years, who were 
uncontrolled on pharmaceutical therapy and who had been 
given SLT treatment. Exclusion criteria were patients who 
could not be followed for at least 4 years. 
  Data recorded from each patient included age, sex, type 
of glaucoma, glaucoma medications and the SLT protocol 
(number of spots and laser power settings). The IOP values 
before and after SLT were also registered. All patients 
continued with the same pharmaceutical treatment after SLT. 
  The SLT protocol consisted of treatment that was 
performed in 90° with the SLT Solo laser (Ellex, 
Mainhausen, Germany) using between 25-30 spots applied to 
the trabecular meshwork. The energy level ranged from 0.6 
to 1.0 mJ. All patients were treated by the same physician 
(E.C.). Apraclonidine was instilled once after SLT treatment. 
Follow-up IOP measurements were obtained at least 1, 6, 12, 
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  The main outcome variable analysed was the time to 
failure after SLT treatment. Failure after SLT was defined as 
any one or more of the following: change in the 
pharmaceutical treatment, performance of a further SLT 
treatment, the patient being sent for surgery. 
  When two eyes of the same patient were treated, one eye 
was chosen at random for analysis. 
Statistical Analysis 
  All data were entered into a database. Success rates were 
determined with the Kaplan-Meier survival analysis. 
Statistical software: STATA (Statacorp, 4905 Lakeway 
Drive, College Station, Texas 77845, USA). 
RESULTS 
  In all, 120 eyes of 120 patients were identified during the 
defined time period. The baseline characteristics of the 
sample are given in Table 1. 
Table  1.  Base-Line Characteristics of the Subjects Included 
in the Study 
 
Characteristic  
Age (SD)  76.5 (11.8) years 
Gender 75%  women 
IOP before SLT (mmHg) (SD)  24.7 (4.6)  
Number of SLT procedures undergone:   
  SLT 1 (%)  74 (62) 
  SLT 2 (%)  38 (32) 
  SLT 3 (%)  5 (4) 
  SLT 4 (%)  3 (2)  
Average number of spots per eye (SD)  26.9 (4.8) 
Average dose per eye (mJ) (SD)  0.88 (0.11)  
Average anterior chamber (0-4) (SD)  3.8 (0.49) 
Average pigmentation (0-3)  0.77 (0.66) 
Diagnosis  
  Exfoliative glaucoma (%)  73 (61) 
  Primary open-angle glaucoma (%)  34 (28) 
  Ocular hypertension (%)   9 (7.5) 
  Pigmentary glaucoma (%)   4 (3.5) 
Number of medications (n) (SD)  1.65 (0.83) 
 
  The average time to failure after SLT was 18 months. 
Success rate of SLT is shown in Fig. (1). 
  Intraocular pressure (IOP) values are shown in Fig. (2). 
The registered IOP was until the eye was classified as 
“failure”. 
DISCUSSION 
  Selective laser trabeculoplasty is a commonly accepted 
therapy for lowering IOP. The present study aims to answer 
the question of the efficiency and duration of IOP reduction 
after SLT over a longer period of time. Long-term follow up 
after SLT treatment has been reported by Gracner T et al. [4] 
showing a success rate of 58% after 48 months. Weinand FS 
& Althen F [5] showed a 4-year success rate of 44% after 
SLT treatment. Juzych et al. [6] in a retrospective study 
comparing ALT with SLT reported a 4-year success rate of 
32% after SLT treatment. In our study, the 4-year success 
rate was 24%. This low success rate may have one of several 
explanations. First, the definition of “success” chosen in our 
study was very strict, thus shortening the time to failure. 
Second, patients were treated over 90°, and this meant that 
the total dose and effect were lower than those in the studies 
presented above. 
 
Fig. (1). Kaplan-Meier survival analysis. 
 
Fig. (2). IOP measurements. Note that the amount of included eyes 
was not the same in the different time points: 6 months (n=82), 12 
months (n=43), 24 months (n=27), 36 months (n=23), 48 months 
(n=20). Eyes were excluded when they were defined as “failure”. 
  In our study, the probability of success one year after 
SLT was 62%. Song et al. [7] showed a very low success 
rate one year after SLT treatment of 15.8% treating over 
180°, but the population studied had an extremely low 
preoperative average intraocular pressure (17.6 mmHg), 
making these results difficult to compare. Weinand FS & 
Althen F [5], treating over 180° of the trabecular meshwork, 
showed a one-year success rate of 60%, comparable to the 
value we observed. This means that SLT treatment over 90° 
probably gives a similar IOP reduction as treating over 180°, 
but this is only true at one year after SLT. The 4-year 
success rate showed by Weinand FS & Althen F was 44%, 
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(24%). Long-term IOP reduction seems to be better when 
laser treatment is delivered over 180°. 
  The reason patients were treated only over 90° was a 
study published by Chen et al. [8] showing similar IOP 
reduction with SLT over 90° as that achieved when SLT was 
delivered over 180°. The authors evaluated the IOP 
reduction at 1, 4, and 7 months after treatment. However, 
Nagar M et al. [9] showed a one-year success rate of 34% 
when eyes were treated over 90°, while the one-year success 
rate was 65% when the eyes were treated over 180°. 
Comparing 180° and 360° the authors found an increased 
success rate, but the difference against treating 180° was not 
significant. The authors concluded that success rates 
motivate treating 360° of the angle at each laser session, 
rather than just 180°. 
  Our study is limited by its retrospective design. One issue 
to be considered is selection bias. All patients were treated at 
a tertiary referral centre where the patient population tends to 
have more advanced glaucoma. The severity of glaucoma 
may have been a factor, and this was not directly evaluated 
in this study. Another possible selection bias is the quite high 
percentage of pseudoexfoliative glaucoma patients included 
in the study (61%). Gracner et al. [10] showed no difference 
in SLT results comparing capsular glaucoma and primary 
open-angle glaucoma. The authors evaluated the short-term 
results for an average of 12 months. It is very possible that 
SLT results in the long term (4 years) are different from 
those in the short term (1 year). Pseudoexfoliative glaucoma 
patients probably require more treatment, and their inclusion 
in this study has increased the failure rate. 
  In conclusion, long-term IOP reduction after SLT seems 
not to hold when eyes are treated over 90°. The authors 
recommend treating patients over 180°, as has traditionally 
been done. We suggest that this will improve the long-term 
results. 
DISCLOSURE 
1) No  commercial  interests. 
2)  Supported in part by a grant from the Karolinska 
Institutet’s Foundation. 
3)  Informed consent: the study was performed with 
informed consent and following all guidelines for 
experimental investigations required by the 
Karolinska Institutet Ethics Committee. 
REFERENCES 
[1]  The Glaucoma Laser Trial Research Group, The Glaucoma Laser 
Trial (GLT) 2. Results of argon laser trabeculoplasty versus topical 
medicines. Ophthalmology 1990; 97: 1403-13. 
[2]  The Glaucoma Laser Trial Research Group. The Glaucoma Laser 
Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. 
Am J Ophthalmol 1995; 120: 718-31. 
[3]  Lee R, Hutnik CM. Projected cost comparison of selective laser 
trabeculoplasty versus glaucoma medication in the Ontario Health 
Insurance Plan. Can J Ophthalmol 2006; 41: 449-56. 
[4]  Gracner T, Falez M, Gracner B, Pahor D. Long-term follow-up of 
selective laser trabeculoplasty in primary open-angle glaucoma. 
Klin Monatsbl Augenheilkd 2006; 223: 743-47. 
[5]  Weinand FS, Althen F. Long-term clinical results of selective laser 
trabeculoplasty in the treatment of primary open angle glaucoma. 
Eur J Ophthalmol 2006; 16: 100-4. 
[6]  Juzych MS, Chopra V, Banitt MR, et al. Comparison of long-term 
outcomes of selective laser trabeculoplasty versus argon laser 
trabeculoplasty in open-angle glaucoma. Ophthalmology 2004; 
111: 1853-1859. 
[7]  Song J, Lee PP, Epstein DL, et al. High failure rate associated with 
180 degrees selective laser trabeculoplasty. J Glaucoma 2005; 14: 
400-408. 
[8]  Chen E, Golchin S, Blomdahl S. A comparison between 90 degrees 
and 180 degrees selective laser trabeculoplasty. J Glaucoma 2004; 
13: 62-65. 
[9]  Nagar M, Ogunyomade A, O'Brart DP, Howes F, Marshall J. A 
randomised, prospective study comparing selective laser 
trabeculoplasty with latanoprost for the control of intraocular 
pressure in ocular hypertension and open angle glaucoma. Br J 
Ophthalmol 2005; 89: 1413-17. 
[10]  Gracner T. Intraocular pressure response of capsular glaucoma and 
primary open-angle glaucoma to selective Nd:YAG laser 
trabeculoplasty: a prospective, comparative clinical trial. Eur J 
Ophthalmol 2002; 12: 287-92. 
 
 
 
 
 
 
 
 
 
Received: October 1, 2010  Revised: February 3, 2011  Accepted: March 4, 2011 
 
© Ayala and Chen; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by- 
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 
 
 
 